Research

Hormonal

Multi-modal anti-obesity medication (mmAOM) therapy yields significantly greater preoperative percent total body weight loss (%TBWL) than GLP-1 receptor agonist monotherapy or non-pharmacologic medically supervised weight loss in patients with BMI ≥ 70 kg/m².

If you have a BMI of 70 or higher and are preparing for weight loss surgery, combining multiple weight loss medications (mmAOM) under medical supervision leads to significantly more weight loss than using just one GLP-1 medication or lifestyle changes alone. This approach helps reduce surgical risks. Discuss with your doctor if a combination therapy is appropriate for your insurance coverage and health profile.

ModerateSupportsMEDIUM confidence
The mmAOM group achieved the highest average - 13.07% - and median (9.93% [5.57–14.29]) %TBWL; followed by Mono-GLP-1 (5.58% [0.98–10.19]); and NP-MSWL (5% [2.97–7.02]).
Michael Kachmar et al. · International Journal of Obesity · 2025

Why this rating

Retrospective, single-institution study with small sample size (n=113) and potential confounding by indication (diabetes prevalence).

Source

Multi-modal neo-adjuvant anti-obesity medications may be more effective than medically supervised weight loss or GLP-1 therapy alone in preparing BMI≥70 patients for metabolic surgery

Michael Kachmar et al. · International Journal of Obesity · 2025

DOI 10.1038/s41366-025-01798-2

cohort · n=113Cited 5×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →